254 related articles for article (PubMed ID: 30546102)
1. Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation.
Ooi CY; Syed SA; Rossi L; Garg M; Needham B; Avolio J; Young K; Surette MG; Gonska T
Sci Rep; 2018 Dec; 8(1):17834. PubMed ID: 30546102
[TBL] [Abstract][Full Text] [Related]
2. Fecal dysbiosis and inflammation in intestinal-specific Cftr knockout mice on regimens preventing intestinal obstruction.
Young SM; Woode RA; Williams EC; Ericsson AC; Clarke LL
Physiol Genomics; 2024 Mar; 56(3):247-264. PubMed ID: 38073491
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosis.
McNally P; Singh A; McColley SA; Davies JC; Higgins M; Liu M; Lu J; Rodriguez-Romero V; Shih JL; Rosenfeld M;
J Cyst Fibros; 2024 May; 23(3):429-435. PubMed ID: 38580563
[TBL] [Abstract][Full Text] [Related]
4. Changes in fecal lipidome after treatment with ivacaftor without changes in microbiome or bile acids.
Bass R; Tanes C; Bittinger K; Li Y; Lee H; Friedman ES; Koo I; Patterson AD; Liu Q; Wu GD; Stallings VA
J Cyst Fibros; 2024 May; 23(3):481-489. PubMed ID: 37813785
[TBL] [Abstract][Full Text] [Related]
5. The effects of ivacaftor on CF fatty acid metabolism: An analysis from the GOAL study.
O'Connor MG; Seegmiller A
J Cyst Fibros; 2017 Jan; 16(1):132-138. PubMed ID: 27473897
[TBL] [Abstract][Full Text] [Related]
6. Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D.
Hoppe JE; Wagner BD; Kirk Harris J; Rowe SM; Heltshe SL; DeBoer EM; Sagel SD
J Cyst Fibros; 2022 Nov; 21(6):950-958. PubMed ID: 35440409
[TBL] [Abstract][Full Text] [Related]
7. Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome.
Marsh R; Dos Santos C; Hanson L; Ng C; Major G; Smyth AR; Rivett D; van der Gast C
Microbiol Spectr; 2023 Aug; 11(5):e0117523. PubMed ID: 37607068
[TBL] [Abstract][Full Text] [Related]
8. Gut Microbiota in Children With Cystic Fibrosis: A Taxonomic and Functional Dysbiosis.
Coffey MJ; Nielsen S; Wemheuer B; Kaakoush NO; Garg M; Needham B; Pickford R; Jaffe A; Thomas T; Ooi CY
Sci Rep; 2019 Dec; 9(1):18593. PubMed ID: 31819107
[TBL] [Abstract][Full Text] [Related]
9. Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice.
Bertolini A; Nguyen M; Zehra SA; Taleb SA; Bauer-Pisani T; Palm N; Strazzabosco M; Fiorotto R
J Hepatol; 2024 Mar; ():. PubMed ID: 38554847
[TBL] [Abstract][Full Text] [Related]
10. Intestinal
Price CE; Valls RA; Ramsey AR; Loeven NA; Jones JT; Barrack KE; Schwartzman JD; Royce DB; Cramer RA; Madan JC; Ross BD; Bliska J; O'Toole GA
mBio; 2024 Feb; 15(2):e0314423. PubMed ID: 38179971
[TBL] [Abstract][Full Text] [Related]
11. The Microbiome in Cystic Fibrosis Pulmonary Disease.
Françoise A; Héry-Arnaud G
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32403302
[TBL] [Abstract][Full Text] [Related]
12. An
Barrack KE; Hampton TH; Valls RA; Surve SV; Gardner TB; Sanville JL; Madan JL; O'Toole GA
J Bacteriol; 2024 Jan; 206(1):e0028623. PubMed ID: 38169295
[TBL] [Abstract][Full Text] [Related]
13. Changes in nutrition and growth status in young children in the first 12 weeks of ivacaftor therapy.
Tindall A; Bass R; Maqbool A; Stallings VA
J Cyst Fibros; 2023 Nov; 22(6):989-995. PubMed ID: 37438197
[TBL] [Abstract][Full Text] [Related]
14. The Gut-Lung Axis in Cystic Fibrosis.
Price CE; O'Toole GA
J Bacteriol; 2021 Sep; 203(20):e0031121. PubMed ID: 34339302
[TBL] [Abstract][Full Text] [Related]
15. Cftr deletion in mouse epithelial and immune cells differentially influence the intestinal microbiota.
Scull CE; Luo M; Jennings S; Taylor CM; Wang G
Commun Biol; 2022 Oct; 5(1):1130. PubMed ID: 36289287
[TBL] [Abstract][Full Text] [Related]
16. The gut microbiota in adults with cystic fibrosis compared to colorectal cancer.
Caley LR; Wood HM; Bottomley D; Fuentes Balaguer A; Wilkinson L; Dyson J; Young C; White H; Benton S; Brearley M; Quirke P; Peckham DG
J Cyst Fibros; 2024 Mar; 23(2):262-268. PubMed ID: 38104000
[TBL] [Abstract][Full Text] [Related]
17. Development of the intestinal microbiome in cystic fibrosis in early life.
Price CE; Hampton TH; Valls RA; Barrack KE; O'Toole GA; Madan JC; Coker MO
mSphere; 2023 Aug; 8(4):e0004623. PubMed ID: 37404016
[TBL] [Abstract][Full Text] [Related]
18. The gut-lung axis in the CFTR modulator era.
Lussac-Sorton F; Charpentier É; Imbert S; Lefranc M; Bui S; Fayon M; Berger P; Enaud R; Delhaes L
Front Cell Infect Microbiol; 2023; 13():1271117. PubMed ID: 37780857
[TBL] [Abstract][Full Text] [Related]
19. Fecal Dysbiosis and Inflammation in Intestinal-Specific Cftr Knockout Mice on Regimens Preventing Intestinal Obstruction.
Young SM; Woode RA; Williams E; Ericsson A; Clarke LL
bioRxiv; 2023 Jul; ():. PubMed ID: 37546931
[TBL] [Abstract][Full Text] [Related]
20. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients.
Cox MJ; Allgaier M; Taylor B; Baek MS; Huang YJ; Daly RA; Karaoz U; Andersen GL; Brown R; Fujimura KE; Wu B; Tran D; Koff J; Kleinhenz ME; Nielson D; Brodie EL; Lynch SV
PLoS One; 2010 Jun; 5(6):e11044. PubMed ID: 20585638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
